2026-20705NoticeWallet

Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Antibody Specifically Binding to Severe Fever With Thrombocytopenia Syndrome Virus Antigen and Use Thereof

Published Date: 10/9/2026

Notice

Summary

The National Institute of Allergy and Infectious Diseases plans to give Korea National Institute of Health an exclusive license to develop and sell a special antibody that targets a dangerous virus causing severe fever and low platelets. This deal helps speed up turning the invention into real-world treatments. Comments or license requests must be sent by October 26, 2026.

Analyzed Economic Effects

3 provisions identified: 1 benefits, 2 costs, 0 mixed.

Exclusive License To Korea National Institute

The National Institute of Allergy and Infectious Diseases plans to grant an exclusive, sublicensable patent license to Korea National Institute of Health for Korean Patent Application No. 10-2025-0196127 (filed December 11, 2025) covering antibodies that bind the SFTS virus antigen. Consolidation of these co-owned rights is intended to give Korea National Institute of Health the sole right to commercialize the invention.

Intended Faster Development of SFTS Treatments

The notice states that consolidating the co-owned patent rights is intended to expedite development of the invention, which covers novel antibodies and diagnostic and pharmaceutical compositions for prevention, diagnosis, mitigation, or treatment of Severe Fever with Thrombocytopenia Syndrome (SFTS) virus infection. This aims to speed commercial development of SFTS-related treatments and diagnostics.

Royalty Terms, Comment Deadline, and Confidentiality

The prospective exclusive license will be royalty-bearing and sublicensable (with sublicenses subject to 37 CFR part 404). Written comments or license applications must be received by October 26, 2026 to be considered; comments and objections (other than license applications) will not be treated confidentially and may be made publicly available, while license applications are presumed to contain confidential business information and will be released only as required under the Freedom of Information Act.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
Comments Due
10/9/2026
10/26/2026

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
National Institutes of Health
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register